Skip to Content
You are currently on the new version of our website. Access the old version .

109 Results Found

  • Review
  • Open Access
8 Citations
3,026 Views
29 Pages

8 January 2026

The mesenchymal–epithelial transition (MET) receptor is a tyrosine kinase activated by its sole known ligand, hepatocyte growth factor (HGF). MET signaling regulates key cellular processes, including proliferation, survival, migration, motility...

(This article belongs to the Special Issue Advances in Precision Medicine: Targeting Known and Emerging Oncogenic Targets in Lung Cancer (2nd Edition))
  • Review
  • Open Access
15 Citations
7,589 Views
19 Pages

12 December 2022

Non-small cell lung cancer (NSCLC) is increasingly being treated with targeted therapies. Savolitinib (Orpathys®) is highly selective mesenchymal epithelial transition (MET)–tyrosine kinase inhibitor (TKI), which is conditionally approved i...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Article
  • Open Access
3 Citations
2,560 Views
14 Pages

Chromosomal Aberrations and Oxidative Stress in Psoriatic Patients with and without Metabolic Syndrome

  • Drahomira Holmannova,
  • Pavel Borsky,
  • Ctirad Andrys,
  • Kvetoslava Hamakova and ,
  • Eva Cermakova,
  • Gabriela Poctova,
  • Zdenek Fiala,
  • Jindra Smejkalova,
  • Vladimir Blaha and
  • Lenka Borska
  • + 5 authors+ 0 author

Psoriasis and metabolic syndrome (MetS), a common comorbidity of psoriasis, are associated with mild chronic systemic inflammation that increases oxidative stress and causes cell and tissue damage. At the cellular level, chromosomal and DNA damage ha...

(This article belongs to the Special Issue Psoriasis and Its Related Metabolic Complications)
  • Review
  • Open Access
21 Citations
4,947 Views
14 Pages

Overview of Molecular Detection Technologies for MET in Lung Cancer

  • Carina Heydt,
  • Michaela Angelika Ihle and
  • Sabine Merkelbach-Bruse

26 May 2023

MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 sk...

(This article belongs to the Special Issue Roles of MET in Cancer Development and Treatment)
  • Review
  • Open Access
26 Citations
8,416 Views
18 Pages

25 January 2024

Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary b...

(This article belongs to the Special Issue Novel Therapeutic Strategies for the Treatment of Brain Tumors)
  • Article
  • Open Access
5 Citations
4,106 Views
16 Pages

MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer

  • Yu-Min Yeh,
  • Pei-Ying Wu,
  • Peng-Chan Lin,
  • Pei-Fang Su and ,
  • Ya-Ting Hsu,
  • Keng-Fu Hsu and
  • Meng-Ru Shen
  • + 2 authors+ 0 author

23 August 2021

An optimal therapeutic regimen for endometrial cancer with extra-uterine metastasis is unavailable. This study aims to improve our understanding of the genomic landscape of advanced endometrial cancer and identify potential therapeutic targets. The c...

  • Review
  • Open Access
33 Citations
14,375 Views
33 Pages

The hepatocyte growth factor (HGF): MET axis is a ligand-mediated receptor tyrosine kinase pathway that is involved in multiple cellular functions, including proliferation, survival, motility, and morphogenesis. Aberrancy in the HGF/MET pathway has b...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Review
  • Open Access
22 Citations
8,787 Views
23 Pages

29 April 2025

Background: Recent research has increasingly highlighted alterations in the proto-oncogene MET, whose abnormal activation has been implicated in multiple cancers. MET encodes c-MET, a receptor tyrosine kinase critical for cellular growth, survival, a...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
42 Citations
14,542 Views
14 Pages

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells

  • Na Song,
  • Shizhou Liu,
  • Jingdong Zhang,
  • Jing Liu and ,
  • Ling Xu,
  • Yunpeng Liu and
  • Xiujuan Qu
  • + 2 authors+ 0 author

4 April 2014

Aberrant MET expression and hepatocyte growth factor (HGF) signaling are implicated in promoting resistance to targeted agents; however, the induced MET activation by epidermal growth factor receptor (EGFR) inhibitors mediating resistance to targeted...

(This article belongs to the Section Biochemistry)
  • Review
  • Open Access
23 Citations
6,510 Views
21 Pages

Polymorphisms of Fat Mass and Obesity-Associated Gene in the Pathogenesis of Child and Adolescent Metabolic Syndrome

  • Yongyan Song,
  • Henry Wade,
  • Bingrui Zhang,
  • Wenhao Xu and ,
  • Rongxue Wu,
  • Shujin Li and
  • Qiaozhu Su
  • + 2 authors+ 0 author

6 June 2023

Childhood metabolic syndrome (MetS) is prevalent around the world and is associated with a high likelihood of suffering from severe diseases such as cardiovascular disease later in adulthood. MetS is associated with genetic susceptibility that involv...

(This article belongs to the Section Nutrition and Metabolism)
  • Review
  • Open Access
40 Citations
9,216 Views
18 Pages

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

  • Nele Van Der Steen,
  • Patrick Pauwels,
  • Ignacio Gil-Bazo,
  • Eduardo Castañon and ,
  • Luis Raez,
  • Federico Cappuzzo and
  • Christian Rolfo
  • + 2 authors+ 0 author

25 March 2015

In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which a...

(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
  • Article
  • Open Access
6 Citations
3,904 Views
17 Pages

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

  • Jiacong Wei,
  • Anna A. Rybczynska,
  • Pei Meng,
  • Martijn Terpstra and ,
  • Ali Saber,
  • Jantine Sietzema,
  • Wim Timens,
  • Ed Schuuring,
  • T. Jeroen N. Hiltermann and
  • Klaas Kok
  • + 8 authors+ 3 authors

1 October 2020

The number of genomic aberrations known to be relevant in making therapeutic decisions for non-small cell lung cancer patients has increased in the past decade. Multiple molecular tests are required to reliably establish the presence of these aberrat...

(This article belongs to the Special Issue New Therapeutic Strategies for Lung Cancer)
  • Article
  • Open Access
13 Citations
6,312 Views
23 Pages

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer

  • Jooseok Kim,
  • Kyung Eui Park,
  • Yoo-Seong Jeong,
  • YeongMun Kim and ,
  • Hayeon Park,
  • Ji-Hye Nam,
  • Kyungsoo Jung,
  • Woo Sung Son,
  • Hun Soon Jung and
  • Young Kee Shin
  • + 14 authors+ 9 authors

15 June 2020

The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplif...

  • Article
  • Open Access
25 Citations
3,414 Views
15 Pages

Decanoic Acid Exerts Its Anti-Tumor Effects via Targeting c-Met Signaling Cascades in Hepatocellular Carcinoma Model

  • Min Hee Yang,
  • Mina Lee,
  • Amudha Deivasigamani,
  • Duc Dat Le and ,
  • Chakrabhavi Dhananjaya Mohan,
  • Kam Man Hui,
  • Gautam Sethi and
  • Kwang Seok Ahn
  • + 3 authors+ 0 author

22 September 2023

DA, one of the medium-chain fatty acids found in coconut oil, is suggested to have diverse biochemical functions. However, its possible role as a chemoprevention agent in HCC has not been deciphered. Aberrant activation of c-Met can modulate tumor gr...

(This article belongs to the Section Methods and Technologies Development)
  • Review
  • Open Access
96 Citations
13,496 Views
13 Pages

Targeting MET Amplification as a New Oncogenic Driver

  • Hisato Kawakami,
  • Isamu Okamoto,
  • Wataru Okamoto,
  • Junko Tanizaki and ,
  • Kazuhiko Nakagawa and
  • Kazuto Nishio
  • + 1 author+ 0 author

22 July 2014

Certain genetically defined cancers are dependent on a single overactive oncogene for their proliferation and survival, a phenomenon known as “oncogene addiction”. A new generation of drugs that selectively target such “driver oncogenes” manifests a...

(This article belongs to the Special Issue MET in Cancer)
  • Article
  • Open Access
24 Citations
6,377 Views
19 Pages

Metabolic syndrome (MetS) pathogenesis involves oxidative stress associated with mitochondrial dysfunction, which triggers integrated stress responses via various compensatory metabolic modulators like mitokines and hepatokines. However, the regulato...

(This article belongs to the Special Issue Exercise Medicine in Health and Disease)
  • Review
  • Open Access
124 Citations
17,250 Views
46 Pages

13 March 2023

Metabolic syndrome (MetS) is considered a metabolic disorder that has been steadily increasing globally and seems to parallel the increasing prevalence of obesity. It consists of a cluster of risk factors which traditionally includes obesity and hype...

(This article belongs to the Section Endocrinology)
  • Article
  • Open Access
1 Citations
2,374 Views
12 Pages

The Effects of Optical Aberrations to Illumination Beam Thickness in Two-Photon Excitation Microscopes

  • Nan Li,
  • Fanglin Luo,
  • Chengliang Yang,
  • Zenghui Peng and ,
  • Li Xuan,
  • Qingpan Bu,
  • Quanquan Mu and
  • Xingyun Zhang
  • + 3 authors+ 0 author

15 July 2022

When performing in vivo imaging of live samples, it is a big challenge to penetrate thick tissues while still maintaining high resolution and a large field of view because of the sample-induced aberrations. These requirements can be met by combining...

(This article belongs to the Section Optics and Lasers)
  • Review
  • Open Access
13 Citations
8,782 Views
13 Pages

c-Met and miRs in Cancer

  • Simona Giglio and
  • Andrea Vecchione

c-Met, a member of the receptor tyrosine kinase family, is involved in a wide range of cellular processes, including tumor survival, cell growth, angiogenesis and metastasis, and resulting in overexpression in many human cancers, leading to a constit...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Feature Paper
  • Review
  • Open Access
3 Citations
8,329 Views
33 Pages

MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  • Kenneth Kin-Wah To,
  • Kwong-Sak Leung and
  • William Chi-Shing Cho

The Met protein is a cell surface receptor tyrosine kinase predominantly expressed in epithelial cells. Aberrant regulation of MET is manifested by numerous mechanisms including amplification, mutations, deletion, fusion of the MET proto-oncogene, an...

(This article belongs to the Section Preclinical Research)
  • Review
  • Open Access
35 Citations
7,682 Views
14 Pages

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer

  • Carminia Maria Della Corte,
  • Morena Fasano,
  • Federica Papaccio,
  • Fortunato Ciardiello and
  • Floriana Morgillo

25 November 2014

The Hepatocyte growth factor (HGF)—mesenchymal-epithelial transition (MET) pathway is deregulated in several cancers and is associated with aggressive phenotype and worse prognosis. MET, a tyrosine kinase receptor activated by HGF, plays a physiolog...

(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
  • Review
  • Open Access
9 Citations
7,122 Views
22 Pages

MET Activation in Lung Cancer and Response to Targeted Therapies

  • Sarah Anna Okun,
  • Daniel Lu,
  • Katherine Sew,
  • Asha Subramaniam and
  • William W. Lockwood

16 January 2025

The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that mediates the activity of a variety of downstream pathways upon its activation. These pathways regulate various physiological processes within the cell, including gro...

(This article belongs to the Special Issue New and Emerging Strategies for Targeting Genomic Instability and Overcoming Drug Resistance in Lung Cancer)
  • Article
  • Open Access
20 Citations
7,024 Views
20 Pages

Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer

  • Yanhua Fan,
  • Huaiwei Ding,
  • Donghwa Kim,
  • Duc-Hiep Bach and ,
  • Ji-Young Hong,
  • Yongnan Xu and
  • Sang Kook Lee
  • + 2 authors+ 0 author

Aberrant activation of hepatocyte growth factor (HGF)/c-Met signaling pathway caused by gene amplification or mutation plays an important role in tumorigenesis. Therefore, c-Met is considered as an attractive target for cancer therapy and c-Met inhib...

(This article belongs to the Special Issue Apoptosis in Cancer)
  • Article
  • Open Access
632 Views
15 Pages

25 June 2026

Aberrant activation of c-MET signaling contributes to tumor progression and resistance to therapy in non-small-cell lung cancer (NSCLC), yet its therapeutic significance remains incompletely understood. In this study, we evaluated c-MET expression an...

(This article belongs to the Section Cell Signaling)
  • Review
  • Open Access
57 Citations
14,872 Views
21 Pages

24 April 2017

Aberrant signaling of the hepatocyte growth factor (HGF)/c-Met pathway has been identified as a promoter of tumorigenesis in several tumor types including head and neck squamous cell carcinoma (HNSCC). Despite a relatively low c-Met mutation frequenc...

(This article belongs to the Special Issue Hepatocyte Growth Factor Pathway in Cancer)
  • Systematic Review
  • Open Access
21 Citations
4,514 Views
25 Pages

Lymphatic Mapping in Colon Cancer Depending on Injection Time and Tracing Agent: A Systematic Review and Meta-Analysis of Prospective Designed Studies

  • Katharina Lucas,
  • Nathaniel Melling,
  • Anastasios D. Giannou,
  • Matthias Reeh and ,
  • Oliver Mann,
  • Thilo Hackert,
  • Jakob R. Izbicki,
  • Daniel Perez and
  • Julia K. Grass
  • + 4 authors+ 0 author

15 June 2023

An optimized lymph node yield leads to better survival in colon cancer, but extended lymphadenectomy is not associated with survival benefits. Lymphatic mapping shows several colon cancers feature aberrant drainage pathways inducing local recurrence...

(This article belongs to the Special Issue Innovations in Diagnosis and Treatment of Colon and Rectal Cancer: Preoperative Optimisation, Multidisciplinary Management, and Surgical Technology Advancement)
  • Article
  • Open Access
11 Citations
4,838 Views
22 Pages

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis

  • Daniel Lu,
  • Amy Nagelberg,
  • Justine LM Chow,
  • Yankuan T Chen and ,
  • Quentin Michalchuk,
  • Romel Somwar and
  • William W. Lockwood
  • + 2 authors+ 0 author

8 March 2022

Targeted therapies for MET exon 14-skipping (METΔex14)-driven lung cancers have generated some promising results but response rates remain below that seen for other kinase-driven cancers. One strategy for improving treatment outcomes is to empl...

(This article belongs to the Special Issue Understanding Molecular Regulation of Cancer Progression and Metastasis)
  • Article
  • Open Access
6 Citations
7,086 Views
15 Pages

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

  • Nele Van Der Steen,
  • Karen Zwaenepoel,
  • Giulia Mazzaschi,
  • Rosa A. Luirink and ,
  • Daan P. Geerke,
  • Ken Op de Beeck,
  • Christophe Hermans,
  • Marcello Tiseo,
  • Paul Van Schil and
  • Patrick Pauwels
  • + 10 authors+ 5 authors

4 December 2019

The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping...

(This article belongs to the Section Medicinal Chemistry)
  • Article
  • Open Access
618 Views
18 Pages

Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma

  • Yunzhan Li,
  • Hanif Khan,
  • Seyma Demirsoy,
  • Muhammad Younis and ,
  • Guilan Shi,
  • Hannah Valensi,
  • William Bernhardt,
  • Jeongwu Lee,
  • Mitchell Machtay and
  • Inan Olmez
  • + 12 authors+ 7 authors

30 August 2026

Glioblastoma (GBM) is the most aggressive primary brain tumor with limited therapeutic options and extremely poor prognosis. Aberrant activation of the receptor tyrosine kinase MET drives tumor progression, therapeutic resistance, and reduced surviva...

(This article belongs to the Special Issue Emerging Therapeutic Strategies for Glioblastoma)
  • Article
  • Open Access
12 Citations
4,396 Views
11 Pages

Correlation of MET and PD-L1 Expression in Malignant Melanoma

  • Kyu Young Song,
  • Sabina Desar,
  • Thomas Pengo,
  • Ryan Shanley and
  • Alessio Giubellino

9 July 2020

The proto-oncogene MET, the hepatocyte growth factor (HGF) receptor, is a transmembrane receptor tyrosine kinase (RTK) with a prominent role in tumor metastasis and resistance to anti-cancer therapies. Melanoma demonstrates relatively frequent MET ab...

(This article belongs to the Section Cancer Biomarkers)
  • Review
  • Open Access
35 Citations
11,542 Views
16 Pages

MET and Small-Cell Lung Cancer

  • Francesco Gelsomino,
  • Giulio Rossi and
  • Marcello Tiseo

13 October 2014

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invar...

(This article belongs to the Special Issue MET in Cancer)
  • Article
  • Open Access
13 Citations
5,103 Views
14 Pages

21 June 2021

Objectives: Patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) ultimately acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) during treatment. In 5–22% of these patients, resistance is mediated b...

  • Article
  • Open Access
9 Citations
3,111 Views
15 Pages

PHA-665752’s Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells

  • Anil Kumar Yadav,
  • Saini Wang,
  • Young-Min Shin and
  • Byeong-Churl Jang

c-Met is a tyrosine-kinase receptor, and its aberrant activation plays critical roles in tumorigenesis, invasion, and metastatic spread in many human tumors. PHA-665752 (PHA) is an inhibitor of c-Met and has antitumor effects on many hematological ma...

(This article belongs to the Collection Feature Papers in Molecular Oncology)
  • Article
  • Open Access
63 Citations
12,228 Views
17 Pages

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

  • Friedhelm Bladt,
  • Manja Friese-Hamim,
  • Christian Ihling,
  • Claudia Wilm and
  • Andree Blaukat

19 August 2014

The mesenchymal-epithelial transition factor (c-Met) is a receptor tyrosine kinase with hepatocyte growth factor (HGF) as its only high-affinity ligand. Aberrant activation of c-Met is associated with many human malignancies, including hepatocellular...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
106 Citations
10,638 Views
20 Pages

26 May 2015

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion...

(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
  • Review
  • Open Access
1 Citations
4,541 Views
13 Pages

29 September 2024

Patients affected by familial hypercholesterolemia possess elevated low-density lipoprotein cholesterol and therefore have greater risk for cardiovascular disease. About 90% of familial hypercholesterolemia cases are associated with aberrant LDLR. Ov...

(This article belongs to the Section Molecular & Translational Genetics)
  • Review
  • Open Access
1 Citations
1,126 Views
25 Pages

The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies

  • Filippos Koinis,
  • Maria Smaragdi Vlachou,
  • Georgios Nintos,
  • Georgios Christodoulopoulos and ,
  • Emmanouil Panagiotidis,
  • Ioannis Eleftheropoulos,
  • Galatea Kallergi,
  • Michail Samarinas and
  • Athanasios Kotsakis
  • + 4 authors+ 0 author

2 May 2026

Background/Objectives: Advanced prostate cancer (PCa) evolves through adaptive mechanisms that sustain tumor growth despite the suppression of androgen receptor (AR) signaling. Accumulating evidence identifies activation of the hepatocyte growth fact...

(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Prostate Cancer: From Biomarkers to Precision Surgery)
  • Article
  • Open Access
7 Citations
4,206 Views
20 Pages

6 April 2021

Background: Lung cancer is the leading cause of cancer death. SIPA1 is a mitogen induced GTPase activating protein (GAP) and may hamper cell cycle progression. SIPA1 has been shown to be involved in MET signaling and may contribute to tight junction...

(This article belongs to the Special Issue Cell Adhesion Molecules in Metastasis)
  • Article
  • Open Access
15 Citations
4,620 Views
12 Pages

Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels

  • Sung-Hwa Sohn,
  • Hee Jung Sul,
  • Bohyun Kim,
  • Bum Jun Kim and ,
  • Hyeong Su Kim and
  • Dae Young Zang
  • + 1 author+ 0 author

21 August 2020

Aberrant expression of mucins (MUCs) can promote the epithelial–mesenchymal transition (EMT), which leads to enhanced tumorigenesis. Carcinogenesis-related pathways involving c-MET and β-catenin are associated with MUCs. In this study, we...

(This article belongs to the Section Molecular Oncology)
  • Case Report
  • Open Access
11 Citations
8,116 Views
15 Pages

Print and Try Technique: 3D-Printing of Teeth with Complex Anatomy a Novel Endodontic Approach

  • Riccardo Tonini,
  • Edit Xhajanka,
  • Massimo Giovarruscio,
  • Federico Foschi and ,
  • Giulia Boschi,
  • Ayfer Atav-Ates,
  • Andrea Cicconetti,
  • Marco Seracchiani,
  • Gianluca Gambarini and
  • Luciano Pacifici
  • + 6 authors+ 1 author

8 February 2021

The purpose of this report is to evaluate the applicability of a novel Print and Try technique in the presence of aberrant endodontic anatomies and to achieve a predictable treatment with improved outcome. According to guidelines, cone beam computed...

(This article belongs to the Special Issue Innovative Techniques in Endodontics)
  • Article
  • Open Access
404 Views
13 Pages

31 August 2026

Oxidative stress disrupts skeletal muscle cell survival and proteostasis, thereby compromising animal skeletal muscle health. As an organic selenium source, selenomethionine (SeMet) participates in antioxidant defense and selenoprotein regulation. Ho...

  • Article
  • Open Access
19 Citations
4,892 Views
12 Pages

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers

  • Yuichi Kumaki,
  • Steve Olsen,
  • Mitsukuni Suenaga,
  • Tsuyoshi Nakagawa and ,
  • Hiroyuki Uetake and
  • Sadakatsu Ikeda
  • + 1 author+ 0 author

26 September 2021

Amplification (amp) of MET can be observed in cases of focal gene copy number gain, such as MET-driven amp, or with a gain of chromosome 7, such as aneuploidy. Several studies have shown that only high-level focal MET amp (MET/CEP7 ratio ≥5) is oncog...

  • Review
  • Open Access
16 Citations
8,288 Views
19 Pages

Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes

  • Chelsy L. Cliff,
  • Bethany M. Williams,
  • Christos E. Chadjichristos,
  • Ulrik Mouritzen and ,
  • Paul E. Squires and
  • Claire E. Hills
  • + 1 author+ 0 author

Of increasing prevalence, diabetes is characterised by elevated blood glucose and chronic inflammation that precedes the onset of multiple secondary complications, including those of the kidney and the eye. As the leading cause of end stage renal dis...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
21 Citations
4,636 Views
20 Pages

High Resolution and Automatable Cytogenetic Biodosimetry Using In Situ Telomere and Centromere Hybridization for the Accurate Detection of DNA Damage: An Overview

  • Radhia M’Kacher,
  • Bruno Colicchio,
  • Steffen Junker,
  • Elie El Maalouf and ,
  • Leonhard Heidingsfelder,
  • Andreas Plesch,
  • Alain Dieterlen,
  • Eric Jeandidier,
  • Patrice Carde and
  • Philippe Voisin
  • + 5 authors+ 0 author

In the event of a radiological or nuclear accident, or when physical dosimetry is not available, the scoring of radiation-induced chromosomal aberrations in lymphocytes constitutes an essential tool for the estimation of the absorbed dose of the expo...

(This article belongs to the Special Issue Effects of Ionizing Radiation in Cancer Radiotherapy)
  • Systematic Review
  • Open Access
27 Citations
4,213 Views
24 Pages

18 January 2022

This systematic review and meta-analysis aims to evaluate the prognostic and clinicopathological significance of the aberrant expression of β-catenin (assessed through the immunohistochemical loss of membrane expression, cytoplasmic and nuclear...

(This article belongs to the Special Issue The Migration and Invasion of Oral Squamous Carcinoma Cells: Matrix, Growth Factor and Signaling Involvement)
  • Article
  • Open Access
1 Citations
1,323 Views
17 Pages

Targeting the c-Met/VEGFR Pathway to Boost Nab-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights

  • Jennifer Huang,
  • Quinn Kaurich,
  • Md Sazzad Hassan,
  • Urs von Holzen and
  • Niranjan Awasthi

3 February 2026

Combination chemotherapy regimens are commonly employed to treat advanced gastric adenocarcinoma (GAC), yet median survival remains less than one year. Nab-paclitaxel has demonstrated significant antitumor activity in preclinical GAC models. Overexpr...

(This article belongs to the Special Issue Gastrointestinal Cancer: From Cellular and Molecular Mechanisms to Therapeutic Opportunities)
  • Article
  • Open Access
14 Citations
7,536 Views
19 Pages

Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors

  • Alan Jiang,
  • Qiufeng Liu,
  • Ruifeng Wang,
  • Peng Wei and ,
  • Yang Dai,
  • Xin Wang,
  • Yechun Xu,
  • Yuchi Ma,
  • Jing Ai and
  • Bing Xiong
  • + 7 authors+ 2 authors

Fibroblast growth factor receptors (FGFRs), a subfamily of receptor tyrosine kinases, are aberrant in various cancer types, and considered to be promising targets for cancer therapy. We started with a weak-active compound that was identified from our...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
30 Citations
11,006 Views
27 Pages

19 December 2013

Radiation therapy remains an imperative treatment modality for numerous malignancies. Enduring significant technical achievements both on the levels of treatment planning and radiation delivery have led to improvements in local control of tumor growt...

(This article belongs to the Special Issue MET in Cancer)
  • Review
  • Open Access
1,011 Views
71 Pages

Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents

  • Siva S. Panda,
  • Mohamed S. Bekheit,
  • Dalia R. Aboshouk,
  • Sudhan Sivakumar and ,
  • Mohamed A. Morsy,
  • Mariam Abdur-Rahman,
  • Abdelgawad Fahmi and
  • Adel S. Girgis
  • + 3 authors+ 0 author

9 September 2026

The hepatocyte growth factor (HGF)/c-Met signaling pathway plays a central role in cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Aberrant c-Met activation, driven by gene amplification, overexpressio...

(This article belongs to the Special Issue Structure-Based Design of Drugs and Other Bioactive Molecules)
  • Review
  • Open Access
31 Citations
6,920 Views
35 Pages

Mitochondria (Mt) are essential cellular organelles for the production of energy and thermogenesis. Mt also serve a host of functions in addition to energy production, which include cell signaling, metabolism, cell death, and aging. Due to the centra...

(This article belongs to the Special Issue Mitochondria as a Cellular Hub in Neurological Disorders)

of 3